Compare Merck & Co., Inc. (MRK) vs Roundhill Innov-100 0DTE Covered Call Strat ETF (QDTE) Price & Performance

Merck & Co., Inc.Trade

Roundhill Innov-100 0DTE Covered Call Strat ETFTrade

Price performance (Past 24H)

Key statistics

Merck & Co., Inc. vs Roundhill Innov-100 0DTE Covered Call Strat ETF — how do they compare? Merck & Co., Inc. trades at $133.23 (market cap $321.77B), while Roundhill Innov-100 0DTE Covered Call Strat ETF trades at $29.76. The key difference: Merck & Co., Inc. pays a 2.61% dividend while Roundhill Innov-100 0DTE Covered Call Strat ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, Roundhill Innov-100 0DTE Covered Call Strat ETF nearer its low. Which is the better fit depends on your goals.

	MRK	QDTE
Market Cap	$321.77B	—
Sector	Health	Income / Options Overlay
52-Week High	$131.84	$36.60
52-Week Low	$77.60	$26.85
Enterprise Value	$368.53B	—
Dividend Yield	2.61%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Merck & Co., Inc.

Merck (MRK) trades at $130.9, up 1.81% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.36. Recent earnings beats and a 72.97% gross margin highlight strong profitability, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock faces headwinds from a high P/E ratio of 104.34 and fluctuating cash flows.

The outlook is positive with robust fundamentals and strategic M&A, but valuation concerns and competitive pressures in pharma pose risks. Upside is likely if earnings growth continues, though investors should monitor debt levels and integration of acquisitions.

Roundhill Innov-100 0DTE Covered Call Strat ETF

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

MRK

Revolution Medicines hits $44B market cap with breakthrough RAS cancer drugs, attracting big pharma interest.24/7 Wall Street · 6 hours agoBullish Bio-Techne reports flat FY2026 revenue, EPS rise, and confirms $11.3B acquisition by Merck KGaA.PRNewsWire · 9 hours agoBullish Trump orders splitting MMR vaccine into three shots despite no scientific support and expert criticism.CNBC · 1 day agoBearish View details →

QDTE

Roundhill Innov-100 0DTE ETF downgraded to hold due to NAV erosion and poor bull market performance.Seeking Alpha · 2 days agoBearish View details →

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

About Roundhill Innov-100 0DTE Covered Call Strat ETF

QDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the NASDAQ 100. It primarily holds a portfolio of U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the NASDAQ 100. This highly tactical strategy aims to maximize option premium capture by exploiting the rapid time decay of options expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.